Based on the Amarin Corporation PLC stock forecast from 1 analysts, the average analyst target price for Amarin Corporation PLC is USD 1.00 over the next 12 months. Amarin Corporation PLC’s average analyst rating is Sell. Stock Target Advisor’s own stock analysis of Amarin Corporation PLC is Slightly Bearish, which is based on 3 positive signals and 6 negative signals. At the last closing, Amarin Corporation PLC’s stock price was USD 0.56. Amarin Corporation PLC’s stock price has changed by +1.12% over the past week, +19.13% over the past month and -48.81% over the last year.
No recent analyst target price found for Amarin Corporation PLC
No recent average analyst rating found for Amarin Corporation PLC
Company Overview Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally to wholesalers and specialty pharmacy providers. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. to develop and commercialize drug products and indications based on the active pharmaceutical ingredient in Vascepa. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was incorporated in 1989 and is headquartered in Dublin, Ireland. Read Less
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a p...Read More
Frequently Asked Questions About Amarin Corporation PLC (AMRN) Stock
Unfortunately we do not have enough data on AMRN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AMRN is USD 1.00 over the next 12 months. The maximum analyst target price is USD 1 while the minimum anlayst target price is USD 1.
AMRN stock's Price/Earning ratio is 73.50.
Our analysis grades AMRN stock's Price / Earning ratio at F. This means that AMRN stock's Price/Earning ratio is above 71% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AMRN may be a overvalued for its sector.
The last closing price of AMRN's stock was USD 0.56.
The most recent market capitalization for AMRN is USD 0.18B.
Based on targets from 1 analysts, the average taret price for AMRN is projected at USD 1.00 over the next 12 months.
This means that AMRN's stock price may go up by +79.21% over the next 12 months.
We can't find any ETFs which contains Amarin Corporation PLC's stock.
As per our most recent records Amarin Corporation PLC has 275 Employees.
Amarin Corporation PLC's registered address is Iconic Offices, The Greenway, Dublin, Ireland, 112-114.
You can get more information about it from Amarin Corporation PLC's website at https://www.amarincorp.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Frequently Asked Questions About Amarin Corporation PLC (AMRN) Stock
Unfortunately we do not have enough data on AMRN's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AMRN is USD 1.00 over the next 12 months. The maximum analyst target price is USD 1 while the minimum anlayst target price is USD 1.
AMRN stock's Price/Earning ratio is 73.50.
Our analysis grades AMRN stock's Price / Earning ratio at F. This means that AMRN stock's Price/Earning ratio is above 71% of the stocks in the Drug Manufacturers - General sector in the NSD exchange.
Based on this AMRN may be a overvalued for its sector.
The last closing price of AMRN's stock was USD 0.56.
The most recent market capitalization for AMRN is USD 0.18B.
Based on targets from 1 analysts, the average taret price for AMRN is projected at USD 1.00 over the next 12 months.
This means that AMRN's stock price may go up by +79.21% over the next 12 months.
We can't find any ETFs which contains Amarin Corporation PLC's stock.
As per our most recent records Amarin Corporation PLC has 275 Employees.
Amarin Corporation PLC's registered address is Iconic Offices, The Greenway, Dublin, Ireland, 112-114.
You can get more information about it from Amarin Corporation PLC's website at https://www.amarincorp.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AMRN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
